

STRONG GROWTH

2015 Net Sales : +7,7%, driven by the company's healthcare activities (+11.8 %)
Sale of the Fragrances & Flavours activities early 2016

Longjumeau, February 2, 2016

PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its 2015 consolidated net sales.

At December 31, 2015, the PCAS Group had generated consolidated net sales of €179.1 million, up by +7.7 % compared to the same period for the previous financial year (+3.8 % at a constant exchange rate).

<i>In €M</i>	2015	2014	% change	2015 At a constant exchange rate	% change
Net sales	179.1	166.4	+7.7 %	172.6	+3.8 %
Pharmaceutical synthesis	120.8	108.1	+11.8 %	115.7	+7.0%
Fine specialty chemicals	58.3	58.3	+0.0 %	57.0	-2.3 %

Pharmaceutical Synthesis (67.5 % of consolidated net sales)

The pharmaceutical synthesis activities generated €120.8 million, up +11.8 % on 2014 (+7.0 % at a constant exchange rate), which confirmed our strategy of positioning our Group as a special partner for pharmaceutical laboratories. Business was supported by the development of new active substances in partnership with leading laboratories and biotech companies, as well as growth in sales of PCAS proprietary molecules, especially active ingredients for generics.

Fine Specialty Chemicals (32.5 % of consolidated net sales)

Net sales of Fine Specialty Chemicals amounted to €58.3 million, which was stable compared to 2014 (-2.3 % at a constant exchange rate). Two contrasting trends can be observed in this segment:

- ✧ The strong progress of performance fine chemicals and new technologies, with gains in market shares in Germany and Asia.
- ✧ A fall in fragrances, flavors and cosmetics, bearing in mind that the fragrances and flavors activities (net sales of €1.8 million in 2015) was sold to the Nactis Flavours Group early 2016.

Outlook for the current year

The company is planning to increase net sales, excluding growth through acquisition, throughout 2016 in both its Pharmaceutical Synthesis and Fine Specialty Chemicals activities.

**NEXT FINANCIAL DISCLOSURE:***2015 results, on February 18, 2016***About PCAS**

PCAS specialises in the development and production of complex molecules for Life Sciences and Innovative Technologies. With 7% of its turnover dedicated to R&D and a wide international presence, PCAS is the preferred industrial partner of market-leading major global groups. The company offers a growing range of proprietary products and solutions in leading-edge segments, and also includes two subsidiaries with very strong potential: Protéus in biotechnology and Enersens in high-performance insulation. With a particularly high standard of performance, PCAS achieved net sales of €179,1 million in 2015 and employs nearly 900 people in six countries.

For more information about PCAS: www.pcas.com

PCAS**NewCap**

Vincent Touraille / Eric Moissenot
PCAS

Emmanuel Huynh / Louis-Victor Delouvrier
NewCap
Financial Communication & investors relations

Tel. : +33 1 69 79 61 32
www.pcas.com

Tel. : +33 1 44 71 98 53
pcas@newcap.eu